Drug
Etravirine clinical trials
Also written TMC125 and Intelence.
- studies test it
- 45
- open now
- 0
- in phase 3
- 9
- first study started
- 2002
How studies write it
Studies that test it under each name
Studies by the year they started
45 studies that test it; most in 2009 (11)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 7 |
| 2009 | 11 |
| 2010 | 5 |
| 2011 | 3 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 14
- Phase 3
- 9
- Phase 4
- 7
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 19
Tibotec Pharmaceuticals, Ireland (13) · ViiV Healthcare (4) · University of North Carolina, Chapel Hill (3) · Tibotec, Inc (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · St Stephens Aids Trust (2) · Janssen Sciences Ireland UC (1) · ANRS, Emerging Infectious Diseases (1)
Often tested with
Tested in the same studies.
Darunavir (11) · Ritonavir (10) · Raltegravir (4) · Darunavir/Ritonavir (3) · Enfuvirtide (2) · Maraviroc (2) · Cobicistat mixture with darunavir (2) · Lopinavir-ritonavir drug combination (2)
Studies
Open first, then newest update. How each study uses etravirine is read from its arms, and is right about nine times in ten.
Testing it · 45
- TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected ParticipantsCompletedPhase 3Janssen Sciences Ireland UCNCT00980538Written as Etravirine
- Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRALCompletedPhase 2ANRS, Emerging Infectious DiseasesNCT02212379Written as raltegravir and etravirine
- A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04208373Written as Etravirine
- Safety and Efficacy of Etravirine in Friedreich Ataxia PatientsCompletedPhase 2IRCCS Eugenio MedeaNCT04273165Written as Etravirine Tablets
- Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)CompletedPhase 1ViiV HealthcareNCT04630002Written as Etravirine (ETR)
- Optimizing Treatment for Treatment-Experienced, HIV-Infected PeopleCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT00537394Written as Etravirine
- Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and ChildrenCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT01504841Written as Etravirine (ETR)
- Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia SuppressionCompletedPhase 3Germans Trias i Pujol HospitalNCT01034917Written as Etravirine 400 mg dissolved in water every 24 hours
- A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral FailureCompletedPhase 4Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT01641367Written as Etravirine
- A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant WomenCompletedPhase 3Janssen Scientific Affairs, LLCNCT00855335Written as Etravirine
- Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected PatientsCompletedPhase 1Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaNCT02818348Written as etravirine
- HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and EtravirineTerminatedPhase 4University of North Carolina, Chapel HillNCT00855413Written as Etravirine
- DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)CompletedPhase 1ViiV HealthcareNCT02063360Written as Etravirine (ETR)
- A Pilot Study of Kaletra and Intelence Tablets in Naive SubjectsCompletedPhase 4Therapeutic ConceptsNCT01045369Written as Kaletra and Intelence Tablets
- Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV InfectionCompletedPhase 2University of North Carolina, Chapel HillNCT00959894Written as Etravirine (Intelence)
- TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and AdolescentsCompletedPhase 2Tibotec Pharmaceuticals, IrelandNCT00665847Written as Etravirine (TMC125)
- A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).CompletedPhase 2Tibotec, IncNCT00534352Written as TMC125; darunavir; ritonavir
- The First Failure StudyTerminatedPhase 4Imperial College LondonNCT01118871Written as Darunavir, Ritonavir and Etravirine
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected PatientsCompletedPhase 4Janssen R&D IrelandNCT01422330Written as Etravirine
- TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.CompletedPhase 3Tibotec Pharmaceuticals, IrelandNCT00254046Written as TMC125
See all 45 studies that test etravirine →
Given in every arm · 1 — etravirine is usual care beside what is tested
As the comparator · 3 — what is tested is compared with etravirine
- A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1TerminatedPhase 2PfizerNCT00823979Written as Etravirine
- Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV InfectionTerminatedPhase 2ViiV HealthcareNCT01199731Written as Etravirine
- A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022TerminatedPhase 2PfizerNCT01254656Written as etravirine
Codes
What other systems call etravirine · ClinicalTrials.gg INT004434
- MeSH (NLM) C451734etravirineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 0C50HW4FO1ETRAVIRINEConfirmed FDA, NLM, Wikidata
- RxNorm 475969Confirmed FDA, Wikidata
- Wikidata Q414762etravirineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73195EtravirineOne source FDA
- DrugBank DB06414One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C451734 | etravirine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 0C50HW4FO1 | ETRAVIRINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 475969 | — | Confirmed FDA, Wikidata |
| Wikidata | Q414762 | etravirine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73195 | Etravirine | One source FDA |
| DrugBank | DB06414 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.